Pfizer Corporation

Delinia, Inc.

Niranjana Aditi Nagarajan

Jeffrey M Greve

Barbra Johnson Sasu

Roman Galetto

Thomas John Van Blarcom

Tao Sai

Siler Panowski

Mathilde Brunnhilde Dusseaux

Surabhi Srivatsa Srinivasan

Jungmin Kim

John Cho

Yoon Park

The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).

Chimeric antigen receptors targeting CD70

This disclosure provides compounds that contain an IL-2 receptor-binding moiety and an ST2-binding moiety. The methods described in the present disclosure provide for a method for treating a condition by administering to a subject in need thereof a therapeutically-effective amount of a compound containing an IL-2 receptor-binding moiety and an ST2-binding moiety.

Multivalent regulatory T cell modulators

Growing community of inventors

Oakland, CA, United States of America

Niranjana Aditi Nagarajan